Document is current
Any future updates will be listed below
-
Authors
Russ, E.
Ziemons, J.
Hillege, L. E.
van Kuijk, S. M. J.
de Jong, E. M.
Elbers, C.
Deenen, M. J.
Borghuis, L. H.
Böhm, T. M. M.
Kristen, P.
Valk, L. C.
van Hellemond, I. E. G.
Vestjens, H.
Dietvorst, A.
Baars, A.
Goosens, A. N. M.
Vermeulen, L.
Buffart, T. E.
de Vos-Geelen, J.
Penders, J.
Redinbo, M. R.
Iersel, L. Valkenburg-van
Smidt, M. L.
-
Funding
Funding for this research was provided by:
the Dutch Research Council, with co-funding from Danone Global Research and Innovation Center and the Clinical Trial Centre Maastricht (CTCM). (NWA.1389.20.165, NWA.1389.20.165, NWA.1389.20.165, NWA.1389.20.165, NWA.1389.20.165, NWA.1389.20.165)
US NIH grant (GM152079)
- License Information
-
More Information
Article History
Received: 31 March 2025
Accepted: 12 June 2025
First Online: 1 July 2025
Declarations
:
: The study will be conducted according to the guidelines of the Declaration of Helsinki and was approved by the Institutional Review Board of Maastricht University Medical Center (RvB/301756/ReWi), the Medical Ethics Committee of azM/UM (METC 2022–3247) as well as the local authorities of participating centers. Written informed consent will be signed by all patients.
: Not applicable.
: JZ and MLS have received research funding from Danone Nutricia Research and Illumina, inc. JVG, and MLS have received institutional research funding from Servier, outside the submitted work. JVG has served as a consultant for Amgen, AstraZeneca, MSD, Pierre Fabre, and Servier, all outside the submitted work. MRR is a founder of Symberix, Inc., which is developing microbiome-targeted therapeutic strategies. MRR has also received research funding from Merck and Lilly, although they were not employed in these studies. MRR was funded by US NIH grant GM152079. L.V. received consultancy fees from Bayer, MSD, Genentech, Servier, and Pierre Fabre, but these had no relation to the content of this publication. L.V. is an employee of Genentech Inc. and shareholder of Roche. All other authors have no competing interests.
